Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill
Highlights
- Pfizer forecast another bumper year in 2022, with a big boost coming from its Covid-19 pill Paxlovid.
- The US drugmaker’s overall revenues in 2021 doubled to $81.3bn.
- The bumper sales prompted accusations from campaigners of ‘pandemic profiteering’ The group Global Justice Now said the annual revenue of $81bn was more than the GDP of most countries.
- The group accused Pfizer of “ripping off public health systems’s money from money from the vaccine monopoly.
- It has charged the NHS £2.8bn above production cost for the 189m doses of the next dose of the vaccine.